BMS 213 Pill - green five-sided
Generic Name: daclatasvir
Pill with imprint BMS 213 is Green, Five-sided and has been identified as Daklinza 30 mg. It is supplied by Bristol-Myers Squibb Company.
Daklinza is used in the treatment of Hepatitis C and belongs to the drug class NS5A inhibitors. Daklinza 30 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for BMS 213
Daklinza
- Generic Name
- daclatasvir
- Imprint
- BMS 213
- Strength
- 30 mg
- Color
- Green
- Shape
- Five-sided
- Availability
- Prescription only
- Drug Class
- NS5A inhibitors
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Bristol-Myers Squibb Company
- National Drug Code (NDC)
- 00003-0213 (Discontinued)
- Inactive Ingredients
-
lactose anhydrous,
microcrystalline cellulose,
croscarmellose sodium,
silicon dioxide,
magnesium stearate,
titanium dioxide,
polyethylene glycol 400,
FD&C Blue No. 2,
indigotindisulfonate sodium,
aluminum oxide,
ferric oxide yellow
Note: Inactive ingredients may vary.
More about Daklinza (daclatasvir)
- Check interactions
- Compare alternatives
- Reviews (10)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: NS5A inhibitors
- Breastfeeding
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
